Modulated expression of WFDC1 during carcinogenesis and cellular senescence

Fibroblasts located adjacent to the tumor [cancer-associated fibroblasts (CAFs)] that constitute a large proportion of the cancer-associated stroma facilitate the transformation process. In this study, we compared the biological behavior of CAFs that were isolated from a prostate tumor to their normal-associated fibroblast (NAF) counterparts. CAFs formed more colonies when seeded at low cell density, exhibited a higher proliferation rate and were less prone to contact inhibition. In contrast to the general notion that high levels of α-smooth muscle actin serve as a marker for CAFs, we found that prostate CAFs express it at a lower level compared with prostate NAFs. Microarray analysis revealed a set of 161 genes that were altered in CAFs compared with NAFs. We focused on whey acidic protein four-disulfide core domain 1 (WFDC1), a known secreted protease inhibitor, and found it to be downregulated in the CAFs. WFDC1 expression was also dramatically downregulated in highly prolific mesenchymal cells and in various cancers including fibrosarcomas and in tumors of the lung, bladder and brain. Overexpression of WFDC1 inhibited the growth rate of the fibrosarcoma HT1080 cell line. Furthermore, WFDC1 level was upregulated in senescent fibroblasts. Taken together, our data suggest an important role for WFDC1 in inhibiting proliferation of both tumors and senescent cells. Finally, we suggest that the downregulation of WFDC1 might serve as a biomarker for cellular transformation.

[1]  R. Weinberg,et al.  The Biology of Cancer , 2006 .

[2]  L. Hayflick THE LIMITED IN VITRO LIFETIME OF HUMAN DIPLOID CELL STRAINS. , 1965, Experimental cell research.

[3]  A. Eisen,et al.  Enhanced collagenase production by fibroblasts derived from human basal cell carcinomas. , 1979, Cancer research.

[4]  H. Dvorak Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. , 1986, The New England journal of medicine.

[5]  A. Gown,et al.  HHF35, a muscle actin-specific monoclonal antibody. II. Reactivity in normal, reactive, and neoplastic human tissues. , 1987, The American journal of pathology.

[6]  A. van den Hooff,et al.  Stromal involvement in malignant growth. , 1988 .

[7]  A. van den Hooff Stromal involvement in malignant growth. , 1988, Advances in cancer research.

[8]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[9]  M. Steiner,et al.  Transforming growth factor-beta 1 overproduction in prostate cancer: effects on growth in vivo and in vitro. , 1992, Molecular endocrinology.

[10]  M. Kattan,et al.  Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[11]  M. Kattan,et al.  Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[12]  M. Gerdes,et al.  Purification of a Novel Protein (ps20) from Urogenital Sinus Mesenchymal Cells with Growth Inhibitory Properties in Vitro(*) , 1995, The Journal of Biological Chemistry.

[13]  M J Bissell,et al.  Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. , 1996, Physiological reviews.

[14]  Z. Werb,et al.  Matrix Metalloproteinase Stromelysin-1 Triggers a Cascade of Molecular Alterations That Leads to Stable Epithelial-to-Mesenchymal Conversion and a Premalignant Phenotype in Mammary Epithelial Cells , 1997, The Journal of cell biology.

[15]  M. Gerdes,et al.  Molecular Cloning and Expression of ps20 Growth Inhibitor , 1998, The Journal of Biological Chemistry.

[16]  M. Gerdes,et al.  Localization of Transforming Growth Factor-β1 and Type II Receptor in Developing Normal Human Prostate and Carcinoma Tissues , 1998, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[17]  C. Harley,et al.  Extension of life-span by introduction of telomerase into normal human cells. , 1998, Science.

[18]  G. Hannon,et al.  Myc activates telomerase. , 1998, Genes & development.

[19]  S. Benchimol,et al.  Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span , 1998, Current Biology.

[20]  Andrea Bodnar,et al.  Human Endothelial Cell Life Extension by Telomerase Expression* , 1999, The Journal of Biological Chemistry.

[21]  P. Hein,et al.  Carcinoma-associated fibroblasts stimulate tumor progression of initiated human epithelium , 2000, Breast Cancer Research.

[22]  G. Ayala,et al.  Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  P. Watson,et al.  Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas , 2002, Nature Genetics.

[24]  M. Yutsudo,et al.  Suppression of anchorage-independent growth of human cancer cell lines by the TRIF52/periostin/OSF-2 gene. , 2002, Experimental cell research.

[25]  Satoshi Matsumoto,et al.  Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas , 2002, Nature Genetics.

[26]  B. Debuire,et al.  Analysis of alterations of WFDC1, a new putative tumour suppressor gene, in hepatocellular carcinoma , 2002, European Journal of Human Genetics.

[27]  J. Cheville,et al.  Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. , 2003, Cancer research.

[28]  M. Larsen,et al.  Promotion of angiogenesis by ps20 in the differential reactive stroma prostate cancer xenograft model. , 2003, Cancer research.

[29]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[30]  G. Gabbiani,et al.  The myofibroblast in wound healing and fibrocontractive diseases , 2003, The Journal of pathology.

[31]  V. Rotter,et al.  Prolonged culture of telomerase-immortalized human fibroblasts leads to a premalignant phenotype. , 2003, Cancer research.

[32]  P. Scardino,et al.  Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  W. Jiang,et al.  Interleukin-7 (IL-7) and IL-7 receptor (IL-7R) signalling complex in human solid tumours. , 2003, Histology and histopathology.

[34]  P. Carroll,et al.  Molecular analysis of WFDC1/ps20 gene in prostate cancer , 2004, The Prostate.

[35]  A. Chinnaiyan,et al.  Integration of high-resolution array comparative genomic hybridization analysis of chromosome 16q with expression array data refines common regions of loss at 16q23–qter and identifies underlying candidate tumor suppressor genes in prostate cancer , 2004, Oncogene.

[36]  R. Tibshirani,et al.  Gene expression profiling identifies clinically relevant subtypes of prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[37]  M. Washington,et al.  TGF-ß Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia , 2004, Science.

[38]  K. Cullen,et al.  Paracrine/autocrine regulation of breast cancer by the insulin-like growth factors , 1998, Breast Cancer Research and Treatment.

[39]  T. Barrette,et al.  ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.

[40]  T. Ratliff TGF-Beta Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia , 2004 .

[41]  J. Campisi,et al.  Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation , 2004, Journal of Cell Science.

[42]  V. Rotter,et al.  Genetic Alterations in p 53 , INK 4 A , and HRas Genes along Defined Stages of Malignant Transformation , 2005 .

[43]  Shinichiro Wachi,et al.  Interactome-transcriptome analysis reveals the high centrality of genes differentially expressed in lung cancer tissues , 2005, Bioinform..

[44]  N. Yoshioka,et al.  Periostin is down‐regulated in high grade human bladder cancers and suppresses in vitro cell invasiveness and in vivo metastasis of cancer cells , 2005, International journal of cancer.

[45]  Dejan Juric,et al.  Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. , 2005, Cancer research.

[46]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[47]  C. Cooper,et al.  Expression analysis onto microarrays of randomly selected cDNA clones highlights HOXB13 as a marker of human prostate cancer , 2004, British Journal of Cancer.

[48]  Dennis C. Sgroi,et al.  Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.

[49]  V. Rotter,et al.  Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation. , 2005, Cancer research.

[50]  Takeshi Shimamura,et al.  Interleukin‐13 receptor α2 chain , 2006 .

[51]  Raghu Kalluri,et al.  Fibroblasts in cancer , 2006, Nature Reviews Cancer.

[52]  Takeshi Shimamura,et al.  Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy. , 2006, Cancer.

[53]  Y. Bourbonnais,et al.  Proteins with whey-acidic-protein motifs and cancer. , 2006, The Lancet. Oncology.

[54]  Carlos Cordon-Cardo,et al.  Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  V. Rotter,et al.  hTERT-immortalized prostate epithelial and stromal-derived cells: an authentic in vitro model for differentiation and carcinogenesis. , 2006, Cancer research.

[56]  J. Campisi,et al.  Cellular senescence: when bad things happen to good cells , 2007, Nature Reviews Molecular Cell Biology.

[57]  Stephanie Schneider,et al.  Allelic loss in a minimal region on chromosome 16q24 is associated with vitreous seeding of retinoblastoma. , 2007, Cancer research.